{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T18:12:10Z","timestamp":1781115130989,"version":"3.54.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journal-of-cardiology.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jjcc.2024.09.002","type":"journal-article","created":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T16:10:55Z","timestamp":1726330255000},"page":"241-247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Incidence and risk factors of hypotension-related adverse events among Japanese patients with heart failure receiving sacubitril\/valsartan or enalapril: Results from the PARALLEL-HF study"],"prefix":"10.1016","volume":"85","author":[{"given":"Hiroyuki","family":"Tsutsui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichi","family":"Momomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Ohishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Iimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihito","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2024.09.002_bb0005","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1161\/CIRCHEARTFAILURE.115.002271","article-title":"Contemporary drug development in heart failure: call for hemodynamically neutral therapies","volume":"8","author":"Vaduganathan","year":"2015","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jjcc.2024.09.002_bb0010","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2024.09.002_bb0015","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1253\/circj.CJ-20-0854","article-title":"Efficacy and safety of sacubitril\/valsartan in Japanese patients with chronic heart failure and reduced ejection fraction: results from the PARALLEL-HF study","volume":"85","author":"Tsutsui","year":"2021","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2024.09.002_bb0020","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2024.09.002_bb0025","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2024.09.002_bb0030","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1253\/circj.CJ-21-0431","article-title":"JCS\/JHFS 2021 guideline focused update on diagnosis and treatment of acute and chronic heart failure","volume":"85","author":"Tsutsui","year":"2021","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2024.09.002_bb0035","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004745","volume":"11","author":"Vardeny","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jjcc.2024.09.002_bb0040","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/eurheartj\/ehw570","article-title":"Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril\/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF","volume":"38","author":"Bohm","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2024.09.002_bb0045","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4070\/kcj.2019.0136","article-title":"Sacubitril\/valsartan in Asian patients with heart failure with reduced ejection fraction","volume":"49","author":"Dewan","year":"2019","journal-title":"Korean Circ J"},{"key":"10.1016\/j.jjcc.2024.09.002_bb0050","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ijcard.2015.02.001","article-title":"Top ten risk factors for morbidity and mortality in patients with chronic systolic heart failure and elevated heart rate: the SHIFT Risk Model","volume":"184","author":"Ford","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jjcc.2024.09.002_bb0055","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ejhf.3066","article-title":"Hypotension in heart failure is less harmful if associated with high or increasing doses of heart failure medication: insights from the Swedish Heart Failure Registry","volume":"26","author":"Girerd","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jjcc.2024.09.002_bb0060","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jjcc.2016.11.011","article-title":"Efficacy and safety of sacubitril\/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: rationale for and design of the randomized, double-blind PARALLEL-HF study","volume":"70","author":"Tsutsui","year":"2017","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2024.09.002_bb0065","author":"International Conference on Harmonization"},{"key":"10.1016\/j.jjcc.2024.09.002_bb0070","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/eurheartj\/ehv330","article-title":"Efficacy and safety of LCZ696 (sacubitril\/valsartan) according to age: insights from PARADIGM-HF","volume":"36","author":"Jhund","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2024.09.002_bb0075","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/eurheartj\/ehx014","article-title":"Sacubitril\/valsartan and low blood pressure in heart failure with reduced ejection fraction","volume":"38","author":"Bruno","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2024.09.002_bb0080","doi-asserted-by":"crossref","DOI":"10.1007\/s10741-018-9757-1","article-title":"Practical guidance on the use of sacubitril\/valsartan for heart failure","volume":"24","author":"Sauer","year":"2019","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jjcc.2024.09.002_bb0085","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jjcc.2023.11.005","article-title":"Relevant adverse events and drug discontinuation of sacubitril\/valsartan in a real-world Japanese cohort: REVIEW-HF registry","volume":"84","author":"Matsumoto","year":"2024","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2024.09.002_bb0090","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2020-001294","article-title":"Beneficial and harmful effects of sacubitril\/valsartan in patients with heart failure: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis","volume":"7","author":"Nielsen","year":"2020","journal-title":"Open Heart"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508724001746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508724001746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T10:33:37Z","timestamp":1746095617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508724001746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0914508724001746"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2024.09.002","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence and risk factors of hypotension-related adverse events among Japanese patients with heart failure receiving sacubitril\/valsartan or enalapril: Results from the PARALLEL-HF study","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2024.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Japanese College of Cardiology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}